Company / R&D Expense
Neogen R&D Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$21.1M
FY2024
5-year range
$17.0M / $26.0M
FY2020-FY2024
Trend
-6.2%
vs FY2023
Sector context
#92 of 105
Health Care
What the data says
Neogen's r&d expense of $21M is lower than 88% of companies in the Health Care sector (FY2024). Declined from $26M to $21M over the past 2 years.
Based on SEC 10-K filings.
$21M in FY2024 with a 5-year CAGR of +7.4%.
Declined from $26M to $21M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +7.3%
- 5-Year CAGR
- +7.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 105This company $21.1M Sector average $284.2M
▼
-92.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +7.4%, indicating consistent growth.
- In FY2024, r&d expense decreased 6.2% year-over-year.
- Ranks #92 out of 105 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.59 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $21.1M | -6.2% |
| FY2023 | $22.5M | -13.7% |
| FY2022 | $26.0M | +52.7% |
| FY2021 | $17.0M | +4.9% |
| FY2020 | $16.2M | +10.1% |
| FY2019 | $14.8M | +15.2% |
| FY2018 | $12.8M | +18.0% |
| FY2017 | $10.9M | +4.5% |
| FY2016 | $10.4M | +5.0% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026